The Administrative Core is responsible for providing administrative and organizational support for the leadership of the Mayo Clinic Breast Cancer SPORE in order to ensure optimal function of all SPORE components, and communications between the SPORE, Mayo Clinic Cancer Center, Mayo Clinic as a whole, other breast SPOREs, other Mayo SPOREs, SPORE collaborations with non-SPORE funding Instruments, and the National Cancer Institute. An important responsibility ofthe Administrative Core is to support the activities of the Breast SPORE Advocacy Advisory Committee and, in particular, facilitate the integration of the project-specific advocates into the activities of their respective projects. This Core is crucial to the optimal integration of all SPORE activities that are necessary for effective and efficient oversight. The Administrative Core will coordinate the activities of the SPORE Executive Committee, the SPORE Advocacy Advisory Committee, the Mayo Inter-SPORE Advisory Committee, the SPORE Internal Scientific Advisory Committee, the SPORE External Advisory Board, and the Breast SPORE Operations Committee. All ofthe committees have specific functions focusing on maximizing the translational research productivity. This Core will also provide administrative support for the activities of the Developmental Research Program and the Career Development Program. The Administrative Core will assist the SPORE Director in coordinating and facilitating the Research Projects and ensuring the proper functioning ofthe Cores in support of the translational research efforts. This Core will coordinate the monthly SPORE scientific meetings, the monthly Key Personnel meetings, the Breast SPORE involvement in the annual Mayo InterSPORE Retreat, and the participation of Breast SPORE investigators in the Annual Translational Science Meeting in Washington, DC. The Core will provide administrative assistance to the SPORE Director in terms of oversight of all SPORE activities including the research projects, functioning ofthe Biospecimen and Pathology Core and the Biostatistics and Patients Registry Core, the Developmental Research Program, the Career Development Program, and all fiscal matters. The Administrative Core will assist the SPORE Director in preparation of all annual Progress Reports to NCI, the competitive renewal application, and all other reports related to the SPORE award.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
(2015) Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Hum Mol Genet 24:285-98
Yee, Douglas (2015) A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. Clin Cancer Res 21:667-9
Ingle, James N; Kalari, Krishna R; Buzdar, Aman U et al. (2015) Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids 99:32-8
Kiiski, Johanna I; Pelttari, Liisa M; Khan, Sofia et al. (2014) Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proc Natl Acad Sci U S A 111:15172-7
Whiley, Phillip J; Parsons, Michael T; Leary, Jennifer et al. (2014) Multifactorial likelihood assessment of BRCA1 and BRCA2 missense variants confirms that BRCA1:c.122A>G(p.His41Arg) is a pathogenic mutation. PLoS One 9:e86836
Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256
D'Assoro, A B; Liu, T; Quatraro, C et al. (2014) The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ER*(+) breast cancer cells. Oncogene 33:599-610
Agarwal, D; Pineda, S; Michailidou, K et al. (2014) FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. Br J Cancer 110:1088-100
Abdel-Aal, Abu-Baker M; Lakshminarayanan, Vani; Thompson, Pamela et al. (2014) Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist. Chembiochem 15:1508-13
Joshi, Poorval M; Sutor, Shari L; Huntoon, Catherine J et al. (2014) Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J Biol Chem 289:9247-53

Showing the most recent 10 out of 202 publications